Though lots of systemic and in-depth researches on the role of the CD39-CD73-adenosine axis in diseases have been implemented, such as cardiovascular diseases, autoimmune disease, gut inflammation, and other cancers, immune checkpoint therapy targeting adenosine pathway in GC is still in the early phase (113, 117–119). Here, NT5E is linked to cancer.